Protalix BioTherapeutics
PLX
#8625
Rank
โ‚ฌ0.12 B
Marketcap
1,70ย โ‚ฌ
Share price
1.15%
Change (1 day)
7.41%
Change (1 year)

Revenue for Protalix BioTherapeutics (PLX)

Revenue in 2024 (TTM): โ‚ฌ41.6 Million

According to Protalix BioTherapeutics 's latest financial reports the company's current revenue (TTM ) is โ‚ฌ44.05 Million. In 2023 the company made a revenue of โ‚ฌ59.24 Million an increase over the revenue in the year 2022 that were of โ‚ฌ44.41 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Protalix BioTherapeutics from 1999 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) โ‚ฌ41.6 M-29.78%
2023 โ‚ฌ59.24 M33.41%
2022 โ‚ฌ44.41 M31.15%
2021 โ‚ฌ33.86 M-33.78%
2020 โ‚ฌ51.13 M4.74%
2019 โ‚ฌ48.82 M9.72%
2018 โ‚ฌ44.49 M177.47%
2017 โ‚ฌ16.03 M83.37%
2016 โ‚ฌ8.74 M-239.98%
2015 -โ‚ฌ6.25 Million-150.12%
2014 โ‚ฌ12.46 M49.52%
2013 โ‚ฌ8.33 M-67.97%
2012 โ‚ฌ26.02 M237.19%
2011 โ‚ฌ7.71 M61.72%
2010 โ‚ฌ4.77 M1662.26%
2009 โ‚ฌ0.27 M
2000 โ‚ฌ0 M-100%
1999 โ‚ฌ3.53 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
โ‚ฌ0.47 B 981.02%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ2.16 B 4,811.21%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ57.99 B 131,528.97%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ16.18 B 36,624.55%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel